Corporate Board Profile
Tech Score: 0/100
Filing Date | Source Excerpt |
---|---|
2015-03-27 | Ms. Crowe is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. 2014 Director Compensation Table shows total compensation of $94,257. |
2016-03-22 | Maria A. Crowe Age 56 Director since 2014 Ms. Crowe is President of Manufacturing Operations for Eli Lilly and Company... Ms. Crowe is a member of our Compensation Committee and Nominating and Corporate Governance Committee. 2015 Director Compensation Table: Maria A. Crowe $215,491 |
2017-03-17 | Maria A. Crowe Age 57 Director since 2014 Ms. Crowe is President of Manufacturing Operations for Eli Lilly and Company... Ms. Crowe is a member of our Compensation Committee and Nominating and Corporate Governance Committee. 2016 Director Compensation Table: Maria A. Crowe $212,301 |
2018-03-19 | Ms. Crowe chairs our Nominating and Corporate Governance Committee and is a member of our Compensation Committee. Each nonemployee Director who served in 2017 was paid at the annual rate of $80,000 for services as a Director. In addition to base compensation, the Lead Director receives an annual fee of $30,000 and the independent Chairman receives an annual fee of $100,000. The following fees were paid for serving on a committee of the Board in 2017. Committee Chairperson fees and member fees are listed. The 2017 Director Compensation Table shows Maria A. Crowe's total compensation as $219,478. |
2019-03-22 | Ms. Crowe chairs our Nominating and Corporate Governance Committee and is a member of our Audit Committee. Each nonemployee Director who served in 2018 was paid a retainer fee of $80,000 as base compensation for services as a Director. In addition to base compensation, the Lead Director received an annual fee of $30,000 and the independent Chairman received an annual fee of $100,000. The following annual fees were paid for serving on a committee of the Board in 2018: Audit Chair $30,000, member $15,000; Compensation Chair $17,500, member $7,500; Nominating & Corporate Governance Chair $17,500, member $7,500. The 2018 Director Compensation Table shows Ms. Crowe's total compensation as $226,579. |
2020-03-17 | Ms. Crowe chairs our Nominating and Corporate Governance Committee and is a member of our Audit Committee. The following table provides the compensation and benefits applicable to our nonemployee Directors for 2019: Maria A. Crowe $235,959 total compensation. |
2021-03-17 | Ms. Crowe chairs our Nominating and Corporate Governance Committee and is a member of our Audit Committee. Ms. Crowe also is a member of our Compensation Committee. The following table provides the compensation and benefits applicable to our nonemployee Directors for 2020: Maria A. Crowe total compensation $205,391. |
2022-03-18 | Maria A. Crowe Retired President of Manufacturing Operations, Eli Lilly and Company Age: 62 Director since 2014 Committees: · Compensation · Nominating and Corporate Governance (Chair) 2021 Director Compensation Table Maria A. Crowe $112,500 Fees Earned or Paid in Cash $120,319 Stock Awards $3,602 All Other Compensation $236,421 Total |
2023-03-20 | Maria A. Crowe Retired President of Manufacturing Operations, Eli Lilly and Company Age: 63 Director since 2014 Committees: Audit, Nominating and Corporate Governance (Chair) 2022 Director Compensation Table: Total $266,394 |
2024-03-14 | Ms. Crowe served as President of Manufacturing Operations for Eli Lilly and Company, a global manufacturer of pharmaceutical products, from 2012 until her retirement in December 2017. Ms. Crowe joined Eli Lilly and Company in 1982 and served in multiple leadership roles of increasing responsibility. Ms. Crowe provides the Board with extensive experience in manufacturing, sourcing and procurement for a global manufacturing company. Ms. Crowe also brings valuable experience on production capacity expansion and innovation efforts. 2023 Director Compensation Table shows total $267,621. |
2025-03-17 | Ms. Crowe served as President of Manufacturing Operations for Eli Lilly and Company, a global manufacturer of pharmaceutical products. |
Data sourced from SEC filings. Last updated: 2025-08-30